Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Management also announced changes to a second, ongoing trial of donanemab, known as Trailblazer-ALZ 2.

Eli Lilly Makes a Case For Its Alzheimer's Drug as Shares Drop

Eli Lilly fell as much as 7% on Tuesday after additional data for its Alzheimer's drug candidate, donanemab, was released in The New England Journal of Medicine and presented at the 2021 International Conference on Alzheimer's and Parkinson's Diseases over the weekend. The data reinforced previously released top-line data that showed donanemab slowed the cognitive decline in patients with early symptoms of dementia.

Eli Lilly falls 7% after its Alzheimer's drug data underwhelms Wall Street

Enthusiasm by the drugmaker for its antibody therapy had helped fuel investors' expectations, analysts say.

Eli Lilly Stock Falls After Alzheimer's Drug Results Disappoint Wall Street

Eli Lilly and Co (NYSE: LLY) gave an in-depth look at its donanemab Phase 2 trial in Alzheimer's disease at the International Conference on Alzheimer's and Parkinson's Diseases. As announced in January, the drug met the trial's primary goal by slowing down the rate of cognitive and daily function decline by 32% compared to a placebo.

Eli Lilly's Stock Is Trading Lower After Donanemab Showed Mixed Data In Mid-Stage Alzheimer's Study

Eli Lilly's latest Alzheimer's disease candidate is a terrific success and a disappointing flop at the same time.

Why Eli Lilly's Successful Alzheimer's Disease Study Was So Disappointing

ShaShares of Eli Lilly & Co. were down 5.2% in premarket trading on Monday, two days after the drug maker said additional clinical-trial data reinforced the role its experimental Alzheimer's disease drug can play in slowing decline among people with early symptomatic forms of the disease. The data was published in the New England Journal of Medicine on Saturday, and it examined results from a Phase 2 study that found donanemab could reduce decline by 32% when compared against placebo at 76 weeks.

Lilly's stock is down after sharing additional clinical data about its Alzheimer's disease drug candidate

INDIANAPOLIS, March 13, 2021 /PRNewswire/ -- Phase 2 TRAILBLAZER-ALZ results presented today by Eli Lilly and Company (NYSE: LLY) at the 15th International Conference on Alzheimer's & Parkinson Diseases™ 2021 (AD/PD™ 2021) held virtually March 9-14, 2021 and published simultaneously in the New England Journal of Medicine (NEJM)  expand on previously reported top-line data that found donanemab met its primary endpoint and showed significant slowing of decline on the integrated Alzheimer's Disease Rating Scale (iADRS), a composite measure of cognition and daily function, in patients with early symptomatic Alzheimer's disease compared to placebo1,2. Additionally, data from secondary analyses showed donanemab consistently slowed cognitive and functional decline, with ranges between 20-40 percent in all secondary endpoints [Clinical Dementia Rating Scale Sum of Boxes (CDR-SB), Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog13), Alzheimer's Disease Cooperative Study-instrumental Activities of Daily Living (ADCS-iADL), Mini-Mental State Examination (MMSE)] with nominal statistical significance at multiple times compared to placebo.

Lilly's donanemab slowed Alzheimer's disease progression in Phase 2 trial: full data presented at AD/PD™ 2021 and published in NEJM

The big pharma firm bolstered the evidence that its antibody therapy slows the disease in early-stage patients.

Eli Lilly Offers More Positive Data on Its Alzheimer's Drug. What Investors Need to Know.

The latest test of Eli Lilly's Alzheimer's disease drug ended with a mixed bag of results, but experts say there are signs the experimental treatment may curb the disease's decimation of cognition and memory.  Lilly gave an in-depth look at the performance of its drug, called donanemab, on Saturday at the International Conference on Alzheimer's and Parkinson's Diseases. The drug met the trial's primary goals, reducing a harmful substance that builds up in the brains of patients with Alzheimer's disease. It also slowed down the rate of cognitive decline by 32%, according to data scheduled to be published Saturday in a medical journal. But it missed the mark on several secondary tests.

New data on Eli Lilly's experimental Alzheimer's drug backs a hotly debated scientific theory, but shows mixed benefits for patients

Eli Lilly stock has been on a charge in recent months owing to the promise of COVID treatment Bamlanivimab and Alzheimer's drug Donanemab. Bamlanivimab contributed $871m of sales in FY20 despite only receiving its EUA in November and may contribute $1-$2bn in FY21, although this estimate may rise.

Eli Lilly: Major Catalysts In Bloom - Alzheimer's Is Key To Share Price Momentum

Lilly's (LLY) combination of its antibody drugs, bamlanivimab and etesevimab cuts death and hospitalizations, per new data from the BLAZE-1 phase III study.

Lilly (LLY) COVID-19 Antibody Combo Cuts Death/Hospitalization

On a chilly spring morning in 2019, Amrit Mula arrived in her office at pharmaceutical giant Eli Lilly and Co's factory in Branchburg, New Jersey, to find a desk drawer open that she had kept locked. Her files were missing.

Special Report: Insider alleges Eli Lilly blocked her efforts to sound alarms about U.S. drug factory

INDIANAPOLIS, March 10, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from programs across its oncology portfolio and pipeline will be presented at the 2021 American Association for Cancer Research (AACR) Annual Meeting, to be held virtually April 10-15, 2021. During the meeting, Lilly Oncology will present data from a study exploring safety and efficacy of its selective RET-kinase inhibitor Retevmo ® (selpercatinib, 40 mg & 80 mg capsules) in patients with rearranged during transfection (RET) fusion-positive cancers outside of lung and thyroid cancer.

Lilly Announces Details of Presentations at 2021 American Association for Cancer Research (AACR)

Lilly's (LLY) shares are up this year mainly due to positive developments related to its antibodies to treat COVID-19 and pipeline.

Lilly (LLY) Outperforms Industry Year to Date: Here's Why

The news comes days before the company is scheduled to release further data on a potential Alzheimer's disease therapy, called donanmeab.

Eli Lilly Has More Positive Data on Its Covid-19 Antibody Therapy

Eli Lilly and Co (NYSE: LLY) has announced new data from BLAZE-1 Phase 3 study, evaluating the combination of bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg in COVID-19 patients. The combination antibody significantly reduced COVID-19 related hospitalizations and deaths (events) in high-risk patients recently diagnosed with COVID-19.

Eli Lilly Reports More Positive Data From Combination Antibody Drug In COVID-19 Trial

Shares of Eli Lilly & Co. gained 0.7% in premarket trading on Wednesday after the drug maker said its COVID-19 antibody cocktail reduced hospitalizations and deaths in 769 high-risk patients who had recently tested positive for the virus. The company said the findings from the randomized, double-blind, placebo-controlled Phase 3 study provide additional support for the emergency authorization that was granted to the combination of bamlanivimab and etesevimab last month.

Lilly shares more data that says its COVID-19 antibody cocktail can cut hospitalizations, deaths

INDIANAPOLIS, March 10, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data from the randomized, double-blind, placebo-controlled BLAZE-1 Phase 3 study, demonstrating bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg together significantly reduced COVID-19 related hospitalizations and deaths ("events") in high-risk patients recently diagnosed with COVID-19. These results provide additional efficacy and safety data that support the use of the dose recently granted both Emergency Use Authorization by the U.S. Food and Drug Administration (FDA) and a positive scientific opinion by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP).

Lilly's bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19

Eli Lilly and Company (LLY) Presents at Barclays Global Healthcare Conference Transcript

Drugmaker Eli Lilly and Co said on Tuesday the chiefs of its manufacturing division and the ethics and compliance department will step down from their roles in the coming months.

Lilly says manufacturing, compliance heads to retire

Eli Lilly and Co (NYSE: LLY) and Biolojic Design Ltd have entered into a research collaboration and license agreement to discover and develop antibody-based therapy for diabetes. The agreement will leverage Biolojic's AI-based multibody platform.

Biolojic Inks Research And Licensing Pact With Eli Lilly For Diabetes Antibody Therapies

INDIANAPOLIS, March 9, 2021 /PRNewswire/ -- New data from 10 studies will be presented by Eli Lilly and Company (NYSE: LLY) at the upcoming virtual International Conference on Alzheimer's & Parkinson Diseases ™  2021 (AD/PD ™  2021), March 9-14, 2021. Lilly will present detailed results of the TRAILBLAZER-ALZ phase 2 study, which showed that donanemab treatment resulted in significant slowing of decline in a composite measure of cognition and daily function in people with early symptomatic Alzheimer's disease (AD) compared to placebo.

Data from Lilly at International Conference on Alzheimer's & Parkinson Diseases 2021™ (AD/PD™ 2021) to Showcase Clinical Advances in Alzheimer's Disease Research

INDIANAPOLIS, March 9, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the upcoming retirement of two executive committee members and the naming of their successors in the company's manufacturing operations and ethics and compliance organizations. Myles O'Neill,...

Lilly Announces Leadership Transitions in Manufacturing and Ethics and Compliance Organizations

INDIANAPOLIS and TEL AVIV, March 8, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Biolojic Design Ltd. ("Biolojic"), a biotechnology company that computationally designs functional antibodies, today announced a research collaboration and license agreement that will leverage...

Lilly and Biolojic Design Announce Research Collaboration to Discover and Develop Antibody Therapies for Diabetes

CHMP recommends approval of Eli Lilly's (LLY) COVID-19 antibody bamlanivimab, alone and in combination with etesevimab in Europe.

News for Eli Lilly Stock (LLY)